OnCo
technologiesTechnologyStandard of care

Multiparameter flow cytometry MRD

Flow cytometry MRD counts leukaemia cells in the bone marrow one at a time by their surface proteins, down to one in ten thousand.

Eight- to ten-colour flow detects leukaemia-associated immunophenotypes or 'different-from-normal' patterns at 10^-4 sensitivity. The most widely available MRD method in AML and ALL; ELN 2021 MRD guidelines define thresholds and timepoints. Next-generation flow (EuroFlow) reaches 10^-5 in myeloma and ALL. In CLL, undetectable MRD (<10^-4) after venetoclax combinations predicts long remission and is a regulatory endpoint.

Generic schematic · not to scale · placeholder for the diagnostics front
Molecular read-out

How it works

Panels of fluorescently tagged antibodies distinguish aberrant blasts from regenerating normal precursors.

Strengths
  • Broadly applicable, fast (same day)
  • Works without a molecular marker
Limitations
  • Operator and lab dependent
  • Sensitivity below molecular methods; immunophenotype shift after therapy

Latest papers

top
Literature trend1 papers in the last 12 monthsHow this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Multiparameter flow cytometry MRD" OR ABSTRACT:"Multiparameter flow cytometry MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Multiparameter flow cytometry MRD, not a curated reading list.

Connected

14top

Pages like this

not linked directly; found by shared links